Tracking the immunopathological response to Pseudomonas aeruginosa during respiratory infections

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Cigana, Cristina ^a   Lorè, Nicola Ivan ^a   Riva, Camilla ^a   De Fino, Ida ^a   Spagnuolo, Lorenza ^a   Sipione, Barbara ^a   Rossi, Giacomo ^b   Nonis, Alessandro ^c   Cabrini, Giulio ^d   Bragonzi, Alessandra ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF CAMERINO   (Italy)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^d UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CYTOKINE;

ANIMAL; CELL LINE; COMPLICATION; CYSTIC FIBROSIS; DISEASE MODEL; HUMAN; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; MICROBIOLOGY; MOUSE; OPPORTUNISTIC INFECTION; PATHOLOGY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RESPIRATORY TRACT INFECTION;

ANIMALS; CELL LINE; CHEMOKINES; CYSTIC FIBROSIS; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, KNOCKOUT; OPPORTUNISTIC INFECTIONS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS;

EID: 84959036726     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep21465     Document Type: Article

References (45)

1. Barinaga, M. Knockout mice offer first animal model for CF. Science 257, 1046-1047 (1992).
2. Cohen, T. S., Prince, A. Cystic fibrosis: a mucosal immunodeficiency syndrome. Nat Med 18, 509-519, doi: 10.1038/nm.2715 (2012).
3. Devereux, G. et al. An observational study of matrix metalloproteinase (MMP)-9 in cystic fibrosis. J Cyst Fibros 13, 557-563, doi: 10.1016/j.jcf.2014.01.010 (2014).
4. Gaggar, A. et al. A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic inflammation. J Immunol 180, 5662-5669, doi: 180/8/5662 (2008).
5. Weathington, N. M. et al. A novel peptide CXCR ligand derived from extracellular matrix degradation during airway inflammation. Nat Med 12, 317-323, doi: nm1361 (2006).
6. Hilliard, T. N. et al. Airway remodelling in children with cystic fibrosis. Thorax 62, 1074-1080, doi: 10.1136/thx.2006.074641 (2007).
7. Reeves, E. P., Bergin, D. A., Murray, M. A., McElvaney, N. G. The involvement of glycosaminoglycans in airway disease associated with cystic fibrosis. ScientificWorldJournal 11, 959-971, doi: 10.1100/tsw.2011.81 (2011).
8. Solic, N., Wilson, J., Wilson, S. J., Shute, J. K. Endothelial activation and increased heparan sulfate expression in cystic fibrosis. Am J Respir Crit Care Med 172, 892-898, doi: 10.1164/rccm.200409-1207OC (2005).
9. Regamey, N., Jeffery, P. K., Alton, E. W., Bush, A., Davies, J. C. Airway remodelling and its relationship to inflammation in cystic fibrosis. Thorax 66, 624-629, doi: 10.1136/thx.2009.134106 (2011).
10. Hamutcu, R. et al. Clinical findings and lung pathology in children with cystic fibrosis. Am J Respir Crit Care Med 165, 1172-1175, doi: 10.1164/ajrccm.165.8.2104090 (2002).
11. Harris, W. T. et al. Myofibroblast differentiation and enhanced TGF-B signaling in cystic fibrosis lung disease. PLoS One 8, e70196, doi: 10.1371/journal.pone.0070196 (2013).
12. Smith, E. E. et al. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc Natl Acad Sci USA 103, 8487-8492, doi: 10.1073/pnas.0602138103 (2006).
13. Marvig, R. L., Sommer, L. M., Molin, S., Johansen, H. K. Convergent evolution and adaptation of Pseudomonas aeruginosa within patients with cystic fibrosis. Nat Genet 47, 57-64, doi: 10.1038/ng.3148 (2015).
14. Stoltz, D. A., Meyerholz, D. K., Welsh, M. J. Origins of cystic fibrosis lung disease. N Engl J Med 372, 351-362, doi: 10.1056/NEJMra1300109 (2015).
15. Bragonzi, A. Murine models of acute and chronic lung infection with cystic fibrosis pathogens. Int J Med Microbiol 300, 584-593, doi: 10.1016/j.ijmm.2010.08.012 (2010).
16. Bragonzi, A. et al. Pseudomonas aeruginosa microevolution during cystic fibrosis lung infection establishes clones with adapted virulence. Am J Respir Crit Care Med 180, 138-145, doi: 10.1164/rccm.200812-1943OC (2009).
17. Lore, N. I. et al. Cystic fibrosis-niche adaptation of Pseudomonas aeruginosa reduces virulence in multiple infection hosts. PLoS One 7, e35648, doi: 10.1371/journal.pone.0035648 (2012).
18. Dechecchi, M. C. et al. Modulators of sphingolipid metabolism reduce lung inflammation. Am J Respir Cell Mol Biol 45, 825-833, doi: 10.1165/rcmb.2010-0457OC (2011).
19. Sagel, S. D., Kapsner, R. K., Osberg, I. Induced sputum matrix metalloproteinase-9 correlates with lung function and airway inflammation in children with cystic fibrosis. Pediatr Pulmonol 39, 224-232, doi: 10.1002/ppul.20165 (2005).
20. Gaggar, A. et al. Matrix metalloprotease-9 dysregulation in lower airway secretions of cystic fibrosis patients. Am J Physiol Lung Cell Mol Physiol 293, L96-L104, doi: 10.1152/ajplung.00492.2006 (2007).
21. Cigana, C., Lore, N. I., Bernardini, M. L., Bragonzi, A. Dampening Host Sensing and Avoiding Recognition in Pseudomonas aeruginosa Pneumonia. Journal of biomedicine & biotechnology 2011, 852513, doi: 10.1155/2011/852513 (2011).
22. Guillot, L. et al. Lung disease modifier genes in cystic fibrosis. The international journal of biochemistry & cell biology 52, 83-93, doi: 10.1016/j.biocel.2014.02.011 (2014).
23. Cigana, C. et al. Pseudomonas aeruginosa exploits lipid A and muropeptides modification as a strategy to lower innate immunity during cystic fibrosis lung infection. PLoS One 4, e8439, doi: 10.1371/journal.pone.0008439 (2009).
24. Snouwaert, J. N. et al. An animal model for cystic fibrosis made by gene targeting. Science 257, 1083-1088 (1992).
25. Mall, M., Grubb, B. R., Harkema, J. R., O'Neal, W. K., Boucher, R. C. Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice. Nat Med 10, 487-493, doi: 10.1038/nm1028 (2004).
26. Kent, G. et al. Lung disease in mice with cystic fibrosis. J Clin Invest 100, 3060-3069, doi: 10.1172/JCI119861 (1997).
27. Durie, P. R., Kent, G., Phillips, M. J., Ackerley, C. A. Characteristic multiorgan pathology of cystic fibrosis in a long-living cystic fibrosis transmembrane regulator knockout murine model. Am J Pathol 164, 1481-1493, doi: 10.1016/S0002-9440(10)63234-8 (2004).
28. Guilbault, C., Saeed, Z., Downey, G. P., Radzioch, D. Cystic fibrosis mouse models. Am J Respir Cell Mol Biol 36, 1-7, doi: 10.1165/rcmb.2006-0184TR (2007).
29. Wilke, M. et al. Mouse models of cystic fibrosis: phenotypic analysis and research applications. J Cyst Fibros 10 Suppl 2, S152-171, doi: 10.1016/S1569-1993(11)60020-9 (2011).
30. Heeckeren, A. et al. Excessive inflammatory response of cystic fibrosis mice to bronchopulmonary infection with Pseudomonas aeruginosa. J Clin Invest 100, 2810-2815, doi: 10.1172/JCI119828 (1997).
31. Mall, M., Grubb, B. R., Harkema, J. R., O'Neal, W. K., Boucher, R. C. Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice. Nat Med 10, 487-493, doi: 10.1038/nm1028 (2004).
32. Gehrig, S. et al. Lack of neutrophil elastase reduces inflammation, mucus hypersecretion, and emphysema, but not mucus obstruction, in mice with cystic fibrosis-like lung disease. Am J Respir Crit Care Med 189, 1082-1092, doi: 10.1164/rccm.201311-1932OC (2014).
33. Fothergill, J. L., Neill, D. R., Loman, N., Winstanley, C., Kadioglu, A. Pseudomonas aeruginosa adaptation in the nasopharyngeal reservoir leads to migration and persistence in the lungs. Nat Commun 5, 4780, doi: 10.1038/ncomms5780 (2014).
34. Yanagihara, K. et al. Role of elastase in a mouse model of chronic respiratory Pseudomonas aeruginosa infection that mimics diffuse panbronchiolitis. J Med Microbiol 52, 531-535, doi: 10.1099/jmm.0.05154-0 (2003).
35. Zhou, Z. et al. The ENaC-overexpressing mouse as a model of cystic fibrosis lung disease. J Cyst Fibros 10 Suppl 2, S172-182, doi: 10.1016/S1569-1993(11)60021-0 (2011).
36. Raju, S. V. et al. Impact of heterozygote CFTR mutations in COPD patients with chronic bronchitis. Respir Res 15, 18, doi: 10.1186/1465-9921-15-18 (2014).
37. Bodas, M., Min, T., Mazur, S., Vij, N. Critical modifier role of membrane-cystic fibrosis transmembrane conductance regulatordependent ceramide signaling in lung injury and emphysema. J Immunol 186, 602-613, doi: 10.4049/jimmunol.1002850 (2011).
38. Sun, H. et al. Tgf-beta downregulation of distinct chloride channels in cystic fibrosis-affected epithelia. PLoS One 9, e106842, doi: 10.1371/journal.pone.0106842 (2014).
39. Guimbellot, J. S. et al. Role of oxygen availability in CFTR expression and function. Am J Respir Cell Mol Biol 39, 514-521, doi: 10.1165/rcmb.2007-0452OC (2008).
40. Trinh, N. T. et al. Deleterious impact of Pseudomonas aeruginosa on cystic fibrosis transmembrane conductance regulator function and rescue in airway epithelial cells. Eur Respir J 45, 1590-1602, doi: 10.1183/09031936.00076214 (2015).
41. Doring, G., Parameswaran, I. G., Murphy, T. F. Differential adaptation of microbial pathogens to airways of patients with cystic fibrosis and chronic obstructive pulmonary disease. FEMS Microbiol Rev 35, 124-146, doi: 10.1111/j.1574-6976.2010.00237. xFMR237 (2011).
42. Gaggar, A. et al. The role of matrix metalloproteinases in cystic fibrosis lung disease. Eur Respir J 38, 721-727, doi: 10.1183/09031936.00173210 (2011).
43. van Heeckeren, A. M., Schluchter, M. D., Drumm, M. L., Davis, P. B. Role of Cftr genotype in the response to chronic Pseudomonas aeruginosa lung infection in mice. Am J Physiol Lung Cell Mol Physiol 287, L944-952, doi: 10.1152/ajplung.00387.2003 (2004).
44. Kukavica-Ibrulj, I., Facchini, M., Cigana, C., Levesque, R. C., Bragonzi, A. Assessing Pseudomonas aeruginosa virulence and the host response using murine models of acute and chronic lung infection. Methods Mol Biol 1149, 757-771, doi: 10.1007/978-1-4939-0473-0-58 (2014).
45. Bragonzi, A. et al. Nonmucoid Pseudomonas aeruginosa expresses alginate in the lungs of patients with cystic fibrosis and in a mouse model. J Infect Dis 192, 410-419, doi: JID33931 (2005).